Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease
Abstract
:1. Introduction
2. Disorders of Lipid Metabolism in the Development and Progression of COPD
3. Participation of ABCA1 in the Regulation of Inflammation in COPD
3.1. Participation of ABCA1 in the Regulation of Inflammation with the Participation of TLR4
3.2. ABCA1 Cross-Links and JAK2/STAT3 Pathways
3.3. Other Mechanisms of ABCA1 Participation in Inflammation
4. Participation of ABCA1 in Phagocytosis and Apoptosis
5. Participation of ABCA1 in the Development of COPD Phenotypes
6. Conclusions
Funding
Conflicts of Interest
References
- May, S.M.; Li, J.T. Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond. Allergy Asthma Proc. 2015, 36, 4–10. [Google Scholar] [CrossRef] [Green Version]
- Quaderi, S.A.; Hurst, J.R. The unmet global burden of COPD. Glob. Health Epidemiol. Genom. 2018, 3, e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soriano, J.B.; Zielinski, J.; Price, D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009, 374, 721–732. [Google Scholar] [CrossRef]
- Barnes, P.J. COPD 2020: New directions needed. Am. J. Physiol. Cell Mol. Physiol. 2020, 319, L884–L886. [Google Scholar] [CrossRef] [PubMed]
- Vogelmeier, C.F.; Criner, G.J.; Martinez, F.J.; Anzueto, A.; Barnes, P.J.; Bourbeau, J.; Celli, B.R.; Chen, R.; Decramer, M.; Fabbri, L.M.; et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch. Bronconeumol. 2017, 53, 128–149. [Google Scholar] [CrossRef] [PubMed]
- Yamasaki, K.; Eeden, S.F.V. Lung Macrophage Phenotypes and Functional Responses: Role in the Pathogenesis of COPD. Int. J. Mol. Sci. 2018, 19, 582. [Google Scholar] [CrossRef] [Green Version]
- Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016, 138, 16–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Russell, R.E.; Culpitt, S.V.; DeMatos, C.; Donnelly, L.; Smith, M.; Wiggins, J.; Barnes, P.J. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2002, 26, 602–609. [Google Scholar] [CrossRef] [Green Version]
- Tabas, I.; Bornfeldt, K.E. Intracellular and Intercellular Aspects of Macrophage Immunometabolism in Atherosclerosis. Circ. Res. 2020, 126, 1209–1227. [Google Scholar] [CrossRef]
- Agustí, A.; Celli, B. Natural history of COPD: Gaps and opportunities. ERJ Open Res. 2017, 3, 117–2017. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oelsner, E.; Balte, P.; Schwartz, J.E.; Burkart, K.M.; Cassano, P.; Jacobs, D.R.; Kalhan, R.; Kronmal, R.; Loehr, L.R.; O’Connor, G.T.; et al. Late-Breaking Abstract: High density lipoprotein cholesterol (HDL-C) and longitudinal lung function in six United States (US) cohorts. Eur. Respir. J. 2016, 48, 2001. [Google Scholar] [CrossRef]
- Burkart, K.M.; Ahmed, F.S.; Watson, K.; Hoffman, E.A.; Burke, G.L.; Barr, R.G. Association Between High Density Lipoproteins (HDL) Cholesterol And CT Percent Emphysema. The MESA Lung Study In B37. Chronic Obstructive Pulmonary Disease Pathogenesis I. Am. J. Crit. Care Med. 2010, 181, A2878. [Google Scholar]
- Park, J.H.; Mun, S.; Choi, D.P.; Lee, J.Y.; Kim, H.C. Association between high-density lipoprotein cholesterol level and pulmonary function in healthy Korean adolescents: The JS high school study. BMC Pulm. Med. 2017, 17, 190. [Google Scholar] [CrossRef] [Green Version]
- Burkart, K.M.; Manichaikul, A.; Wilk, J.B.; Ahmed, F.S.; Burke, G.L.; Enright, P.; Hansel, N.N.; Haynes, D.; Heckbert, S.R.; Hoffman, E.A.; et al. APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur. Respir. J. 2014, 43, 1003–1017. [Google Scholar] [CrossRef] [Green Version]
- Li, H.; Liu, Y.; Wang, L.; Shen, T.; Du, W.; Liu, Z.; Chen, R.; Hu, M. High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease. Lipids Health Dis. 2016, 15, 59. [Google Scholar] [CrossRef] [Green Version]
- Can, U.; Yerlikaya, F.H.; Yosunkaya, S. Role of oxidative stress and serum lipid levels in stable chronic obstructive pulmonary disease. J. Chin. Med. Assoc. 2015, 78, 702–708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xuan, L.; Han, F.; Gong, L.; Lv, Y.; Wan, Z.; Liu, H.; Zhang, D.; Jia, Y.; Yang, S.; Ren, L.; et al. Association between chronic obstructive pulmonary disease and serum lipid levels: A meta-analysis. Lipids Health Dis. 2018, 17, 263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zafirova-Ivanovska, B.; Stojkovikj, J.; Dokikj, D.; Anastasova, S.; Debresliovska, A.; Zejnel, S.; Stojkovikj, D. The Level of Cholesterol in COPD Patients with Severe and Very Severe Stage of the Disease. Open Access Maced J. Med. Sci. 2016, 4, 277–282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, Y.; Jiang, B.; Miao, X.; Ma, J.; Wang, J.; Ding, K.; Chen, X.; Hu, Q.; Fu, F.; Zeng, T.; et al. The Relationship of Lymphocyte to High-Density Lipoprotein Ratio with Pulmonary Function in COPD. Int. J. Chron Obstruct Pulmon Dis. 2020, 15, 3159–3169. [Google Scholar] [CrossRef] [PubMed]
- Reed, R.M.; Hashmi, S.; Eberlein, M.; Iacono, A.; Netzer, G.; DeFilippis, A.; Girgis, R.E.; Toth, P.P.; Scharf, S.; Jones, S. Impact of lung transplantation on serum lipids in COPD. Respir. Med. 2011, 105, 1961–1968. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soria-Florido, M.T.; Schroder, H.; Grau, M.; Fito, M.; Lassale, C. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis 2020, 302, 36–42. [Google Scholar] [CrossRef]
- Bandeali, S.; Farmer, J. High-density lipoprotein and atherosclerosis: The role of antioxidant activity. Curr. Atheroscler. Rep. 2012, 14, 101–107. [Google Scholar] [CrossRef]
- Morgan, A.D.; Zakeri, R.; Quint, J.K. Defining the relationship between COPD and CVD: What are the implications for clinical practice? Ther. Adv. Respir. Dis. 2018, 12, 524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takahashi, S.; Betsuyaku, T. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir. Investig. 2015, 53, 259–270. [Google Scholar] [CrossRef]
- Reed, R.M.; Iacono, A.; DeFilippis, A.; Eberlein, M.; Girgis, R.E.; Jones, S. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J. Heart. Lung Transpl. 2011, 30, 674–678. [Google Scholar] [CrossRef] [PubMed]
- Chai, A.B.; Ammit, A.J.; Gelissen, I.C. Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation. Respir. Res. 2017, 18, 41. [Google Scholar] [CrossRef] [Green Version]
- Bochem, A.E.; van der Valk, F.M.; Tolani, S.; Stroes, E.S.; Westerterp, M.; Tall, A.R. Increased Systemic and Plaque Inflammation in ABCA1 Mutation Carriers With Attenuation by Statins. Arter. Thromb. Vasc. Biol. 2015, 35, 1663–1669. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qian, H.; Zhao, X.; Cao, P.; Lei, J.; Yan, N.; Gong, X. Structure of the Human Lipid Exporter ABCA1. Cell 2017, 169, 1228–1239. [Google Scholar] [CrossRef] [Green Version]
- Nagao, K.; Kimura, Y.; Mastuo, M.; Ueda, K. Lipid outward translocation by ABC proteins. FEBS Lett. 2010, 584, 2717–2723. [Google Scholar] [CrossRef] [Green Version]
- Wellington, C.L.; Walker, E.K.; Suarez, A.; Kwok, A.; Bissada, N.; Singaraja, R.; Yang, Y.Z.; Zhang, L.H.; James, E.; Wilson, J.E.; et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Investig. 2002, 82, 273–283. [Google Scholar] [CrossRef] [Green Version]
- Jessup, W.; Gelissen, I.C.; Gaus, K.; Kritharides, L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 2006, 17, 247–257. [Google Scholar] [CrossRef] [PubMed]
- Westerterp, M.; Bochem, A.E.; Yvan-Charvet, L.; Murphy, A.J.; Wang, N.; Tall, A.R. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 2014, 114, 157–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Neufeld, E.B.; Remaley, A.T.; Demosky, S.J.; Stonik, J.A.; Cooney, A.M.; Comly, M.; Dwyer, N.K.; Zhang, M.; Blanchette-Mackie, J.; Santamarina-Fojo, S.; et al. Cellular localization and trafficking of the human ABCA1 transporter. J. Biol. Chem. 2001, 276, 27584–27590. [Google Scholar] [CrossRef] [Green Version]
- Kaminski, W.E.; Piehler, A.; Wenzel, J.J. ABC A-subfamily transporters: Structure, function and disease. Biochim. Biophys. Acta 2006, 1762, 510–524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Orso, E.; Broccardo, C.; Kaminski, W.E.; Bottcher, A.; Liebisch, G.; Drobnik, W.; Gotz, A.; Chambenoit, O.; Diederich, W.; Langmann, T.; et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat. Genet. 2000, 24, 192–196. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, A.R.; Abe-Dohmae, S.; Ohnishi, T.; Aoki, R.; Morinaga, G.; Okuhira, K.; Ikeda, Y.; Kano, F.; Matsuo, M.; Kioka, N.; et al. Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. J. Biol. Chem. 2003, 278, 8815–8819. [Google Scholar] [CrossRef]
- Yin, K.; Liao, D.F.; Tang, C.K. ATP-binding membrane cassette transporter A1 (ABCA1): A possible link between inflammation and reverse cholesterol transport. Mol. Med. 2010, 16, 438–449. [Google Scholar] [CrossRef] [Green Version]
- Francone, O.L.; Aiello, R.J. ABCA1: Regulation, function and relationship to atherosclerosis. Curr. Opin. Investig. Drugs 2002, 3, 415–419. [Google Scholar] [PubMed]
- Zanotti, I.; Poti, F.; Pedrelli, M.; Favari, E.; Moleri, E.; Franceschini, G.; Calabresi, L.; Bernini, F. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J. Lipid. Res. 2008, 49, 954–960. [Google Scholar] [CrossRef] [Green Version]
- Hussein, M.A.; Shrestha, E.; Ouimet, M.; Barrett, T.J.; Leone, S.; Moore, K.J.; Herault, Y.; Fisher, E.A.; Garabedian, M.J. LXR-Mediated ABCA1 Expression and Function Are Modulated by High Glucose and PRMT2. PLoS ONE 2015, 10, e0135218. [Google Scholar] [CrossRef] [Green Version]
- Chawla, A.; Boisvert, W.A.; Lee, C.H.; Laffitte, B.A.; Barak, Y.; Joseph, S.B.; Liao, D.; Nagy, L.; Edwards, P.A.; Curtiss, L.K.; et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 2001, 7, 161–171. [Google Scholar] [CrossRef]
- Pan, H.; Zheng, Y.; Pan, Q.; Chen, H.; Chen, F.; Wu, J.; Di, D. Expression of LXRbeta, ABCA1 and ABCG1 in human triplenegative breast cancer tissues. Oncol. Rep. 2019, 42, 1869–1877. [Google Scholar] [CrossRef] [Green Version]
- Park, Y.; Pham, T.X.; Lee, J. Lipopolysaccharide represses the expression of ATP-binding cassette transporter G1 and scavenger receptor class B, type I in murine macrophages. Inflamm. Res. 2012, 61, 465–472. [Google Scholar] [CrossRef] [PubMed]
- He, P.; Gelissen, I.C.; Ammit, A.J. Regulation of ATP binding cassette transporter A1 (ABCA1) expression: Cholesterol-dependent and-independent signaling pathways with relevance to inflammatory lung disease. Respir. Res. 2020, 21, 250. [Google Scholar] [CrossRef]
- Wong, J.; Quinn, C.M.; Brown, A.J. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem. J. 2006, 400, 485–491. [Google Scholar] [CrossRef] [Green Version]
- Wang, N.; Tall, A.R. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arter. Thromb. Vasc. Biol. 2003, 23, 1178–1184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Venkateswaran, A.; Laffitte, B.A.; Joseph, S.B.; Mak, P.A.; Wilpitz, D.C.; Edwards, P.A.; Tontonoz, P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA 2000, 97, 12097–12102. [Google Scholar] [CrossRef] [Green Version]
- Soumian, S.; Albrecht, C.; Davies, A.H.; Gibbs, R.G. ABCA1 and atherosclerosis. Vasc. Med. 2005, 10, 109–119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, P.; Smith, A.; Gelissen, I.C.; Ammit, A.J. The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. Pharmacol. Rep. 2019, 71, 1219–1226. [Google Scholar] [CrossRef] [PubMed]
- Jacobo-Albavera, L.; Dominguez-Perez, M.; Medina-Leyte, D.J.; Gonzalez-Garrido, A.; Villarreal-Molina, T. The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease. Int. J. Mol. Sci. 2021, 22, 593. [Google Scholar] [CrossRef] [PubMed]
- Kielar, D.; Dietmaier, W.; Langmann, T.; Aslanidis, C.; Probst, M.; Naruszewicz, M.; Schmitz, G. Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin. Chem. 2001, 47, 2089–2097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bates, S.R.; Tao, J.Q.; Yu, K.J.; Borok, Z.; Crandall, E.D.; Collins, H.L.; Rothblat, G.H. Expression and biological activity of ABCA1 in alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol. 2008, 38, 283–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vedhachalam, C.; Ghering, A.B.; Davidson, W.S.; Lund-Katz, S.; Rothblat, G.H.; Phillips, M.C. ABCA1-induced cell surface binding sites for ApoA-I. Arter. Thromb. Vasc. Biol. 2007, 27, 1603–1609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Landry, Y.D.; Denis, M.; Nandi, S.; Bell, S.; Vaughan, A.M.; Zha, X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J. Biol. Chem. 2006, 281, 36091–36101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tall, A.R.; Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 2015, 15, 104–116. [Google Scholar] [CrossRef] [Green Version]
- Birrell, M.A.; Catley, M.C.; Hardaker, E.; Wong, S.; Willson, T.M.; McCluskie, K.; Leonard, T.; Farrow, S.N.; Collins, J.L.; Haj-Yahia, S.; et al. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J. Biol. Chem. 2007, 282, 31882–31890. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, C.; Houston, B.A.; Storey, C.; LeBoeuf, R.C. Both STAT3 activation and cholesterol efflux contribute to the anti-inflammatory effect of apoA-I/ABCA1 interaction in macrophages. J. Lipid Res. 2016, 57, 848–857. [Google Scholar] [CrossRef] [Green Version]
- Francone, O.L.; Royer, L.; Boucher, G.; Haghpassand, M.; Freeman, A.; Brees, D.; Aiello, R.J. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arter. Thromb. Vasc. Biol. 2005, 25, 1198–1205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, Y.; Ishibashi, M.; Seimon, T.; Lee, M.; Sharma, S.M.; Fitzgerald, K.A.; Samokhin, A.O.; Wang, Y.; Sayers, S.; Aikawa, M.; et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ. Res. 2009, 104, 455–465. [Google Scholar] [CrossRef]
- Zhu, X.; Owen, J.S.; Wilson, M.D.; Li, H.; Griffiths, G.L.; Thomas, M.J.; Hiltbold, E.M.; Fessler, M.B.; Parks, J.S. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 2010, 51, 3196–3206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sonett, J.; Goldklang, M.; Sklepkiewicz, P.; Gerber, A.; Trischler, J.; Zelonina, T.; Westerterp, M.; Lemaitre, V.; Okada, Y.; D’Armiento, J. A critical role for ABC transporters in persistent lung inflammation in the development of emphysema after smoke exposure. FASEB J. 2018, 13, 81. [Google Scholar] [CrossRef]
- Song, W.; Wang, W.; Dou, L.Y.; Wang, Y.; Xu, Y.; Chen, L.F.; Yan, X.W. The implication of cigarette smoking and cessation on macrophage cholesterol efflux in coronary artery disease patients. J. Lipid Res. 2015, 56, 682–691. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fessler, M.B. A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease. Ann. Am. Thorac. Soc. 2017, 14, S399–S405. [Google Scholar] [CrossRef] [PubMed]
- Wilson, A.M.; Nair, P.; Hargreave, F.E.; Efthimiadis, A.E.; Anvari, M.; Allen, C.J.; Group, E.R.S. Lipid and smoker’s inclusions in sputum macrophages in patients with airway diseases. Respir. Med. 2011, 105, 1691–1695. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Basset-Leobon, C.; Lacoste-Collin, L.; Aziza, J.; Bes, J.C.; Jozan, S.; Courtade-Saidi, M. Cut-off values and significance of Oil Red O-positive cells in bronchoalveolar lavage fluid. Cytopathology 2010, 21, 245–250. [Google Scholar] [CrossRef]
- Korhonen, J.T.; Olkkonen, V.M.; Lahesmaa, R.; Puolakkainen, M. ABC-cassette transporter 1 (ABCA1) expression in epithelial cells in Chlamydia pneumoniae infection. Microb. Pathog. 2013, 61–62, 57–61. [Google Scholar] [CrossRef]
- Dusuel, A.; Deckert, V.; de Barros, J.P.P.; van Dongen, K.; Choubley, H.; Charron, E.; Le Guern, N.; Labbe, J.; Mandard, S.; Grober, J.; et al. Human cholesteryl ester transfer protein lacks lipopolysaccharide transfer activity, but worsens inflammation and sepsis outcomes in mice. J. Lipid Res. 2020, 62, 100011. [Google Scholar] [CrossRef]
- Shrestha, S.; Wu, B.J.; Guiney, L.; Barter, P.J.; Rye, K.A. Cholesteryl ester transfer protein and its inhibitors. J. Lipid Res. 2018, 59, 772–783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bates, S.R.; Tao, J.Q.; Collins, H.L.; Francone, O.L.; Rothblat, G.H. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am. J. Physiol. Cell Mol. Physiol. 2005, 289, L980–L989. [Google Scholar] [CrossRef] [PubMed]
- McNeish, J.; Aiello, R.J.; Guyot, D.; Turi, T.; Gabel, C.; Aldinger, C.; Hoppe, K.L.; Roach, M.L.; Royer, L.J.; de Wet, J.; et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. USA 2000, 97, 4245–4250. [Google Scholar] [CrossRef] [Green Version]
- Wang, W.; Xu, H.; Shi, Y.; Nandedkar, S.; Zhang, H.; Gao, H.; Feroah, T.; Weihrauch, D.; Schulte, M.L.; Jones, D.W.; et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J. Lipid Res. 2010, 51, 2560–2570. [Google Scholar] [CrossRef] [Green Version]
- Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22, 240–273. [Google Scholar] [CrossRef] [Green Version]
- Di Stefano, A.; Ricciardolo, F.L.M.; Caramori, G.; Adcock, I.M.; Chung, K.F.; Barnes, P.J.; Brun, P.; Leonardi, A.; Ando, F.; Vallese, D.; et al. Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. Eur. Respir. J. 2017, 49, 36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Basu, S.; Fenton, M.J. Toll-like receptors: Function and roles in lung disease. Am. J. Physiol. Cell Mol. Physiol. 2004, 286, L887–L892. [Google Scholar] [CrossRef]
- Zhang, X.; Shan, P.; Jiang, G.; Cohn, L.; Lee, P.J. Toll-like receptor 4 deficiency causes pulmonary emphysema. J. Clin. Investig. 2006, 116, 3050–3059. [Google Scholar] [CrossRef] [PubMed]
- Haw, T.J.; Starkey, M.R.; Pavlidis, S.; Fricker, M.; Arthurs, A.L.; Nair, P.M.; Liu, G.; Hanish, I.; Kim, R.Y.; Foster, P.S.; et al. Toll-like receptor 2 and 4 have opposing roles in the pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease. Am. J. Physiol. Cell Mol. Physiol. 2018, 314, L298–L317. [Google Scholar] [CrossRef] [PubMed]
- Bhagwani, A.; Thompson, A.A.R.; Farkas, L. When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension. Front. Med. 2020, 7, 352. [Google Scholar] [CrossRef]
- Zhang, X.; Shan, P.; Qureshi, S.; Homer, R.; Medzhitov, R.; Noble, P.W.; Lee, P.J. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J. Immunol. 2005, 175, 4834–4838. [Google Scholar] [CrossRef]
- Sarir, H.; Mortaz, E.; Karimi, K.; Kraneveld, A.D.; Rahman, I.; Caldenhoven, E.; Nijkamp, F.P.; Folkerts, G. Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages. J. Inflamm. 2009, 6, 12. [Google Scholar] [CrossRef] [Green Version]
- Karimi, K.; Sarir, H.; Mortaz, E.; Smit, J.J.; Hosseini, H.; De Kimpe, S.J.; Nijkamp, F.P.; Folkerts, G. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir. Res. 2006, 7, 66. [Google Scholar] [CrossRef] [Green Version]
- Kleinridders, A.; Schenten, D.; Konner, A.C.; Belgardt, B.F.; Mauer, J.; Okamura, T.; Wunderlich, F.T.; Medzhitov, R.; Bruning, J.C. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab. 2009, 10, 249–259. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.Y.; Sohn, K.H.; Rhee, S.H.; Hwang, D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 2001, 276, 16683–16689. [Google Scholar] [CrossRef] [Green Version]
- Shi, H.; Kokoeva, M.V.; Inouye, K.; Tzameli, I.; Yin, H.; Flier, J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Investig. 2006, 116, 3015–3025. [Google Scholar] [CrossRef] [PubMed]
- Rogero, M.M.; Calder, P.C. Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. Nutrients 2018, 10, 432. [Google Scholar] [CrossRef] [Green Version]
- Dasu, M.R.; Devaraj, S.; Park, S.; Jialal, I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010, 33, 861–868. [Google Scholar] [CrossRef] [Green Version]
- Mauerer, R.; Ebert, S.; Langmann, T. High glucose, unsaturated and saturated fatty acids differentially regulate expression of ATP-binding cassette transporters ABCA1 and ABCG1 in human macrophages. Exp. Mol. Med. 2009, 41, 126–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mattson, F.H.; Grundy, S.M. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J. Lipid Res. 1985, 26, 194–202. [Google Scholar] [CrossRef]
- Hu, Y.W.; Ma, X.; Li, X.X.; Liu, X.H.; Xiao, J.; Mo, Z.C.; Xiang, J.; Liao, D.F.; Tang, C.K. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 2009, 204, e35–e43. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Oram, J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J. Biol. Chem. 2005, 280, 35896–35903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Phillips, M.C. Is ABCA1 a lipid transfer protein? J. Lipid Res. 2018, 59, 749–763. [Google Scholar] [CrossRef] [Green Version]
- Ogawa, E.; Nakano, Y.; Ohara, T.; Muro, S.; Hirai, T.; Sato, S.; Sakai, H.; Tsukino, M.; Kinose, D.; Nishioka, M.; et al. Body mass index in male patients with COPD: Correlation with low attenuation areas on CT. Thorax 2009, 64, 20–25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McDonald, M.N.; Wouters, E.F.M.; Rutten, E.; Casaburi, R.; Rennard, S.I.; Lomas, D.A.; Bamman, M.; Celli, B.; Agusti, A.; Tal-Singer, R.; et al. It’s more than low BMI: Prevalence of cachexia and associated mortality in COPD. Respir. Res. 2019, 20, 100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stoll, P.; Foerster, S.; Virchow, J.C.; Lommatzsch, M. Overweight is a predictor of long-term survival in hospitalised patients with exacerbations of COPD. Respir. Med. 2016, 116, 59–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, Z.; Yang, D.; Ge, Z.; Yan, M.; Wu, N.; Liu, Y. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: A retrospective real world research. J. Thorac. Dis. 2018, 10, 5086–5099. [Google Scholar] [CrossRef]
- Blum, A.; Simsolo, C.; Sirchan, R.; Haiek, S. "Obesity paradox" in chronic obstructive pulmonary disease. ISR Med. Assoc. J. 2011, 13, 672–675. [Google Scholar]
- Spelta, F.; Pasini, A.M.F.; Cazzoletti, L.; Ferrari, M. Body weight and mortality in COPD: Focus on the obesity paradox. Eat Weight. Disord. 2018, 23, 15–22. [Google Scholar] [CrossRef] [PubMed]
- Wu, T.D.; Ejike, C.O.; Wise, R.A.; McCormack, M.C.; Brigham, E.P. Investigation of the Obesity Paradox in Chronic Obstructive Pulmonary Disease, According to Smoking Status, in the United States. Am. J. Epidemiol. 2019, 188, 1977–1983. [Google Scholar] [CrossRef] [PubMed]
- Yao, H.; Rahman, I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol. Appl. Pharmacol. 2011, 254, 72–85. [Google Scholar] [CrossRef] [Green Version]
- Di Stefano, A.; Caramori, G.; Oates, T.; Capelli, A.; Lusuardi, M.; Gnemmi, I.; Ioli, F.; Chung, K.F.; Donner, C.F.; Barnes, P.J.; et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 2002, 20, 556–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gingo, M.R.; Silveira, L.J.; Miller, Y.E.; Friedlander, A.L.; Cosgrove, G.P.; Chan, E.D.; Maier, L.A.; Bowler, R.P. Tumour necrosis factor gene polymorphisms are associated with COPD. Eur. Respir. J. 2008, 31, 1005–1012. [Google Scholar] [CrossRef] [PubMed]
- Leong, K.G.; Karsan, A. Signaling pathways mediated by tumor necrosis factor alpha. Histol. Histopathol. 2000, 15, 1303–1325. [Google Scholar] [CrossRef] [PubMed]
- Kusnadi, A.; Park, S.H.; Yuan, R.; Pannellini, T.; Giannopoulou, E.; Oliver, D.; Lu, T.; Park-Min, K.H.; Ivashkiv, L.B. The Cytokine TNF Promotes Transcription Factor SREBP Activity and Binding to Inflammatory Genes to Activate Macrophages and Limit Tissue Repair. Immunity 2019, 51, 241–257. [Google Scholar] [CrossRef] [PubMed]
- Hayden, M.S.; Ghosh, S. Regulation of NF-kappaB by TNF family cytokines. Semin. Immunol. 2014, 26, 253–266. [Google Scholar] [CrossRef] [Green Version]
- Gerbod-Giannone, M.C.; Li, Y.; Holleboom, A.; Han, S.; Hsu, L.C.; Tabas, I.; Tall, A.R. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl. Acad. Sci. USA 2006, 103, 3112–3117. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.F.; Yang, X.F.; Cheng, B.; Mei, C.L.; Li, Q.X.; Xiao, H.; Zeng, Q.T.; Liao, Y.H.; Liu, K. Protective effect of Astragalus polysaccharides on ATP binding cassette transporter A1 in THP-1 derived foam cells exposed to tumor necrosis factor-alpha. Phytother. Res. 2010, 24, 393–398. [Google Scholar] [CrossRef] [PubMed]
- Ruysschaert, J.M.; Lonez, C. Role of lipid microdomains in TLR-mediated signalling. Biochim. Biophys. Acta 2015, 1848, 1860–1867. [Google Scholar] [CrossRef]
- Viard, M.; Parolini, I.; Sargiacomo, M.; Fecchi, K.; Ramoni, C.; Ablan, S.; Ruscetti, F.W.; Wang, J.M.; Blumenthal, R. Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J. Virol. 2002, 76, 11584–11595. [Google Scholar] [CrossRef] [Green Version]
- Hakomori, S.; Handa, K.; Iwabuchi, K.; Yamamura, S.; Prinetti, A. New insights in glycosphingolipid function: "glycosignaling domain," a cell surface assembly of glycosphingolipids with signal transducer molecules, involved in cell adhesion coupled with signaling. Glycobiology 1998, 8, 51–54. [Google Scholar] [CrossRef] [Green Version]
- Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature 1997, 387, 569–572. [Google Scholar] [CrossRef]
- Fantini, J.; Epand, R.M.; Barrantes, F.J. Cholesterol-Recognition Motifs in Membrane Proteins. Adv. Exp. Med. Biol. 2019, 1135, 3–25. [Google Scholar] [CrossRef]
- Sharpe, L.J.; Rao, G.; Jones, P.M.; Glancey, E.; Aleidi, S.M.; George, A.M.; Brown, A.J.; Gelissen, I.C. Cholesterol sensing by the ABCG1 lipid transporter: Requirement of a CRAC motif in the final transmembrane domain. Biochim. Biophys. Acta 2015, 1851, 956–964. [Google Scholar] [CrossRef] [PubMed]
- Fantini, J.; Barrantes, F.J. How cholesterol interacts with membrane proteins: An exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. Front. Physiol. 2013, 4, 31. [Google Scholar] [CrossRef] [Green Version]
- Li, H.; Papadopoulos, V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology 1998, 139, 4991–4997. [Google Scholar] [CrossRef]
- Baier, C.J.; Fantini, J.; Barrantes, F.J. Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor. Sci. Rep. 2011, 1, 69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Epand, R.M. Proteins and cholesterol-rich domains. Biochim. Biophys. Acta 2008, 1778, 1576–1582. [Google Scholar] [CrossRef] [Green Version]
- Epand, R.M.; Thomas, A.; Brasseur, R.; Epand, R.F. Cholesterol interaction with proteins that partition into membrane domains: An overview. Subcell Biochem. 2010, 51, 253–278. [Google Scholar] [CrossRef] [PubMed]
- Fantini, J.; Barrantes, F.J. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim. Biophys. Acta 2009, 1788, 2345–2361. [Google Scholar] [CrossRef] [PubMed]
- Frisdal, E.; Lesnik, P.; Olivier, M.; Robillard, P.; Chapman, M.J.; Huby, T.; Guerin, M.; Le Goff, W. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J. Biol. Chem. 2011, 286, 30926–30936. [Google Scholar] [CrossRef] [Green Version]
- Castrillo, A.; Joseph, S.B.; Vaidya, S.A.; Haberland, M.; Fogelman, A.M.; Cheng, G.; Tontonoz, P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 2003, 12, 805–816. [Google Scholar] [CrossRef]
- Guo, L.; Chen, C.H.; Zhang, L.L.; Cao, X.J.; Ma, Q.L.; Deng, P.; Zhu, G.; Gao, C.Y.; Li, B.H.; Pi, Y.; et al. IRAK1 mediates TLR4-induced ABCA1 downregulation and lipid accumulation in VSMCs. Cell Death Dis. 2015, 6, e1949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tarling, E.J.; de Vallim, T.Q.A.; Edwards, P.A. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol. Metab. 2013, 24, 342–350. [Google Scholar] [CrossRef] [Green Version]
- Gulshan, K.; Brubaker, G.; Conger, H.; Wang, S.; Zhang, R.; Hazen, S.L.; Smith, J.D. PI(4,5)P2 Is Translocated by ABCA1 to the Cell Surface Where It Mediates Apolipoprotein A1 Binding and Nascent HDL Assembly. Circ. Res. 2016, 119, 827–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Doughman, R.L.; Firestone, A.J.; Anderson, R.A. Phosphatidylinositol phosphate kinases put PI4,5P(2) in its place. J. Membr. Biol. 2003, 194, 77–89. [Google Scholar] [CrossRef] [PubMed]
- Yin, H.L.; Janmey, P.A. Phosphoinositide regulation of the actin cytoskeleton. Annu. Rev. Physiol. 2003, 65, 761–789. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Thapa, N.; Hedman, A.C.; Anderson, R.A. Phosphatidylinositol 4,5-bisphosphate: Targeted production and signaling. Bioessays 2013, 35, 513–522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoneda, A.; Kanemaru, K.; Matsubara, A.; Takai, E.; Shimozawa, M.; Satow, R.; Yamaguchi, H.; Nakamura, Y.; Fukami, K. Phosphatidylinositol 4,5-bisphosphate is localized in the plasma membrane outer leaflet and regulates cell adhesion and motility. Biochem. Biophys. Res. Commun. 2020, 527, 1050–1056. [Google Scholar] [CrossRef] [PubMed]
- Patra, M.C.; Choi, S. Insight into Phosphatidylinositol-Dependent Membrane Localization of the Innate Immune Adaptor Protein Toll/Interleukin 1 Receptor Domain-Containing Adaptor Protein. Front. Immunol. 2018, 9, 75. [Google Scholar] [CrossRef] [Green Version]
- Kagan, J.C.; Medzhitov, R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006, 125, 943–955. [Google Scholar] [CrossRef] [Green Version]
- Bonham, K.S.; Orzalli, M.H.; Hayashi, K.; Wolf, A.I.; Glanemann, C.; Weninger, W.; Iwasaki, A.; Knipe, D.M.; Kagan, J.C. A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction. Cell 2014, 156, 705–716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ciesielska, A.; Matyjek, M.; Kwiatkowska, K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol. Life Sci. 2021, 78, 1233–1261. [Google Scholar] [CrossRef] [PubMed]
- Li, L.C.; Varghese, Z.; Moorhead, J.F.; Lee, C.T.; Chen, J.B.; Ruan, X.Z. Cross-talk between TLR4-MyD88-NF-kappaB and SCAP-SREBP2 pathways mediates macrophage foam cell formation. Am. J. Physiol. Heart Circ. Physiol. 2013, 304, H874–H884. [Google Scholar] [CrossRef] [PubMed]
- Aksoy, E.; Taboubi, S.; Torres, D.; Delbauve, S.; Hachani, A.; Whitehead, M.A.; Pearce, W.P.; Berenjeno, I.M.; Nock, G.; Filloux, A.; et al. The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat. Immunol. 2012, 13, 1045–1054. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Plociennikowska, A.; Zdioruk, M.I.; Traczyk, G.; Swiatkowska, A.; Kwiatkowska, K. LPS-induced clustering of CD14 triggers generation of PI(4,5)P2. J. Cell Sci. 2015, 128, 4096–4111. [Google Scholar] [CrossRef] [Green Version]
- Tang, C.; Vaughan, A.M.; Oram, J.F. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J. Biol. Chem. 2004, 279, 7622–7628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agassandian, M.; Miakotina, O.L.; Andrews, M.; Mathur, S.N.; Mallampalli, R.K. Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha-RXR. Biochem. J. 2007, 403, 409–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, G.J.; Yin, K.; Fu, Y.C.; Tang, C.K. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol. Med. 2012, 18, 149–158. [Google Scholar] [CrossRef] [PubMed]
- Vaughan, A.M.; Tang, C.; Oram, J.F. ABCA1 mutants reveal an interdependency between lipid export function, apoA-I binding activity, and Janus kinase 2 activation. J. Lipid Res. 2009, 50, 285–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, C.; Liu, Y.; Kessler, P.S.; Vaughan, A.M.; Oram, J.F. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 2009, 284, 32336–32343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Williams, L.M.; Sarma, U.; Willets, K.; Smallie, T.; Brennan, F.; Foxwell, B.M. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 2007, 282, 6965–6975. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murray, P.J. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 2006, 6, 379–386. [Google Scholar] [CrossRef]
- Hao, X.R.; Cao, D.L.; Hu, Y.W.; Li, X.X.; Liu, X.H.; Xiao, J.; Liao, D.F.; Xiang, J.; Tang, C.K. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009, 203, 417–428. [Google Scholar] [CrossRef]
- Akcora, B.O.; Gabriel, A.V.; Ortiz-Perez, A.; Bansal, R. Pharmacological inhibition of STAT3 pathway ameliorates acute liver injury in vivo via inactivation of inflammatory macrophages and hepatic stellate cells. FASEB Bioadv. 2020, 2, 77–89. [Google Scholar] [CrossRef] [PubMed]
- Gao, H.; Ward, P.A. STAT3 and suppressor of cytokine signaling 3: Potential targets in lung inflammatory responses. Expert Opin Ther. Targets 2007, 11, 869–880. [Google Scholar] [CrossRef] [PubMed]
- Geraghty, P.; Wyman, A.E.; Garcia-Arcos, I.; Dabo, A.J.; Gadhvi, S.; Foronjy, R. STAT3 modulates cigarette smoke-induced inflammation and protease expression. Front. Physiol. 2013, 4, 267. [Google Scholar] [CrossRef] [Green Version]
- Bohadana, A.; Teculescu, D.; Martinet, Y. Mechanisms of chronic airway obstruction in smokers. Respir. Med. 2004, 98, 139–151. [Google Scholar] [CrossRef] [Green Version]
- Carlier, F.; Detry, B.; Sibille, Y.; Pilette, C. STAT-3 is activated in COPD airway epithelial cells. ERJ Open Res. 2019, 5, 214. [Google Scholar] [CrossRef]
- Qu, P.; Roberts, J.; Li, Y.; Albrecht, M.; Cummings, O.W.; Eble, J.N.; Du, H.; Yan, C. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009, 63, 341–347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruwanpura, S.M.; McLeod, L.; Miller, A.; Jones, J.; Vlahos, R.; Ramm, G.; Longano, A.; Bardin, P.G.; Bozinovski, S.; Anderson, G.P.; et al. Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice. Am. J. Physiol. Cell Mol. Physiol. 2012, 302, L627–L639. [Google Scholar] [CrossRef] [Green Version]
- Li, H.; Huang, C.; Huang, K.; Wu, W.; Jiang, T.; Cao, J.; Feng, Z.; Qiu, Z. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS ONE 2011, 6, e25941. [Google Scholar] [CrossRef]
- Camporeale, A.; Poli, V. IL-6, IL-17 and STAT3: A holy trinity in auto-immunity? Front. Biosci. 2012, 17, 2306–2326. [Google Scholar] [CrossRef] [Green Version]
- Du, W.; Hong, J.; Wang, Y.C.; Zhang, Y.J.; Wang, P.; Su, W.Y.; Lin, Y.W.; Lu, R.; Zou, W.P.; Xiong, H.; et al. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. J. Cell Mol. Med. 2012, 16, 1878–1888. [Google Scholar] [CrossRef]
- Chung, K.F.; Adcock, I.M. Multifaceted mechanisms in COPD: Inflammation, immunity, and tissue repair and destruction. Eur. Respir. J. 2008, 31, 1334–1356. [Google Scholar] [CrossRef] [PubMed]
- Yew-Booth, L.; Birrell, M.A.; Lau, M.S.; Baker, K.; Jones, V.; Kilty, I.; Belvisi, M.G. JAK-STAT pathway activation in COPD. Eur. Respir. J. 2015, 46, 843–845. [Google Scholar] [CrossRef] [Green Version]
- Schindler, C.; Strehlow, I. Cytokines and STAT signaling. Adv. Pharmacol. 2000, 47, 113–174. [Google Scholar] [CrossRef] [PubMed]
- Fitzgerald, M.L.; Mujawar, Z.; Tamehiro, N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010, 211, 361–370. [Google Scholar] [CrossRef] [Green Version]
- Eickmeier, O.; Huebner, M.; Herrmann, E.; Zissler, U.; Rosewich, M.; Baer, P.C.; Buhl, R.; Schmitt-Grohe, S.; Zielen, S.; Schubert, R. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 2010, 50, 152–157. [Google Scholar] [CrossRef] [PubMed]
- Hlapcic, I.; Belamaric, D.; Bosnar, M.; Kifer, D.; Dugac, A.V.; Rumora, L. Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters. Diagnostics 2020, 10, 29. [Google Scholar] [CrossRef] [PubMed]
- Murray, P.J. The JAK-STAT signaling pathway: Input and output integration. J. Immunol. 2007, 178, 2623–2629. [Google Scholar] [CrossRef] [Green Version]
- Singh, S.; Verma, S.K.; Kumar, S.; Ahmad, M.K.; Nischal, A.; Singh, S.K.; Dixit, R.K. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. Immunol. Lett. 2018, 196, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Jiang, J.X.; Zhang, S.J.; Shen, H.J.; Guan, Y.; Liu, Q.; Zhao, W.; Jia, Y.L.; Shen, J.; Yan, X.F.; Xie, Q.M. Rac1 signaling regulates cigarette smoke-induced inflammation in the lung via the Erk1/2 MAPK and STAT3 pathways. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1778–1788. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, R.; Tanni, S.E.; Caram, L.M.; Correa, C.; Correa, C.R.; Godoy, I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir. Res. 2013, 14, 24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fielding, C.A.; McLoughlin, R.M.; McLeod, L.; Colmont, C.S.; Najdovska, M.; Grail, D.; Ernst, M.; Jones, S.A.; Topley, N.; Jenkins, B.J. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 2008, 181, 2189–2195. [Google Scholar] [CrossRef]
- Gabay, C. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 2006, 8 (Suppl. 2). [Google Scholar] [CrossRef] [Green Version]
- Niemand, C.; Nimmesgern, A.; Haan, S.; Fischer, P.; Schaper, F.; Rossaint, R.; Heinrich, P.C.; Muller-Newen, G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 2003, 170, 3263–3272. [Google Scholar] [CrossRef] [Green Version]
- Perez-Baos, S.; Barrasa, J.I.; Gratal, P.; Larranaga-Vera, A.; Prieto-Potin, I.; Herrero-Beaumont, G.; Largo, R. Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: Understanding the lipid paradox associated with rheumatoid arthritis. Br. J. Pharmacol. 2017, 174, 3018–3031. [Google Scholar] [CrossRef] [Green Version]
- Yin, K.; Deng, X.; Mo, Z.C.; Zhao, G.J.; Jiang, J.; Cui, L.B.; Tan, C.Z.; Wen, G.B.; Fu, Y.; Tang, C.K. Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: Role of ATP-binding membrane cassette transporter A1 and signal transducer and activator of transcription 3. J. Biol. Chem. 2011, 286, 13834–13845. [Google Scholar] [CrossRef] [Green Version]
- Mills, C.D.; Kincaid, K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 2000, 164, 6166–6173. [Google Scholar] [CrossRef] [Green Version]
- de la Roche, M.; Hamilton, C.; Mortensen, R.; Jeyaprakash, A.A.; Ghosh, S.; Anand, P.K. Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation. J. Cell Biol. 2018, 217, 3560–3576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nunez, G.; Schnurr, M.; et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464, 1357–1361. [Google Scholar] [CrossRef] [Green Version]
- Rajamaki, K.; Lappalainen, J.; Oorni, K.; Valimaki, E.; Matikainen, S.; Kovanen, P.T.; Eklund, K.K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS ONE 2010, 5, e11765. [Google Scholar] [CrossRef] [Green Version]
- Sheedy, F.J.; Grebe, A.; Rayner, K.J.; Kalantari, P.; Ramkhelawon, B.; Carpenter, S.B.; Becker, C.E.; Ediriweera, H.N.; Mullick, A.E.; Golenbock, D.T.; et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 2013, 14, 812–820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Westerterp, M.; Fotakis, P.; Ouimet, M.; Bochem, A.E.; Zhang, H.; Molusky, M.M.; Wang, W.; Abramowicz, S.; la Gemert, S.B.; Wang, N.; et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation 2018, 138, 898–912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Nardo, D.; De Nardo, C.M.; Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am. J. Pathol. 2014, 184, 42–54. [Google Scholar] [CrossRef] [Green Version]
- Colarusso, C.; Terlizzi, M.; Molino, A.; Pinto, A.; Sorrentino, R. Role of the inflammasome in chronic obstructive pulmonary disease (COPD). Oncotarget 2017, 8, 81813–81824. [Google Scholar] [CrossRef] [Green Version]
- Fu, J.-J.; Mao, B.; Wang, S.-J.; Xiao, W.; Li, G.-H.; Wu, L.-H. The activation of NLRP3 inflammasome pathway in COPD is limited in local airways. Eur. Respir. J. 2018, 52, 4981. [Google Scholar] [CrossRef]
- Xiao, W.; Fu, J.-J.; Wang, S.-J.; Wang, Y.; Miao, T.-W.; Mao, B. Andrographolide inhibits the activation of NLRP3 inflammasome in patients with COPD. Eur. Respir. J. 2018, 52, 5246. [Google Scholar] [CrossRef]
- Ghosh, B.; Gaike, A.H.; Pyasi, K.; Brashier, B.; Das, V.V.; Londhe, J.D.; Juvekar, S.; Shouche, Y.S.; Donnelly, L.E.; Salvi, S.S.; et al. Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. Eur. Respir. J. 2019, 53, 73. [Google Scholar] [CrossRef] [PubMed]
- Sidletskaya, K.; Vitkina, T.; Denisenko, Y. The Role of Toll-Like Receptors 2 and 4 in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Int. J. Chron. Obstruct Pulmon. Dis. 2020, 15, 1481–1493. [Google Scholar] [CrossRef]
- D’Anna, S.E.; Balbi, B.; Cappello, F.; Carone, M.; Di Stefano, A. Bacterial-viral load and the immune response in stable and exacerbated COPD: Significance and therapeutic prospects. Int. J. Chron. Obstruct Pulmon. Dis. 2016, 11, 445–453. [Google Scholar] [CrossRef] [Green Version]
- Kaplan, R.; Gan, X.; Menke, J.G.; Wright, S.D.; Cai, T.Q. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J. Lipid Res. 2002, 43, 952–959. [Google Scholar] [CrossRef]
- Grabiec, A.M.; Hussell, T. The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin. Immunopathol. 2016, 38, 409–423. [Google Scholar] [CrossRef] [Green Version]
- Arienti, S.; Barth, N.D.; Dorward, D.A.; Rossi, A.G.; Dransfield, I. Regulation of Apoptotic Cell Clearance During Resolution of Inflammation. Front. Pharmacol. 2019, 10, 891. [Google Scholar] [CrossRef] [Green Version]
- Poon, I.K.; Lucas, C.D.; Rossi, A.G.; Ravichandran, K.S. Apoptotic cell clearance: Basic biology and therapeutic potential. Nat. Rev. Immunol. 2014, 14, 166–180. [Google Scholar] [CrossRef] [Green Version]
- Morimoto, K.; Janssen, W.J.; Fessler, M.B.; McPhillips, K.A.; Borges, V.M.; Bowler, R.P.; Xiao, Y.Q.; Kench, J.A.; Henson, P.M.; Vandivier, R.W. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol. 2006, 176, 7657–7665. [Google Scholar] [CrossRef] [Green Version]
- Mukaro, V.R.; Hodge, S. Airway clearance of apoptotic cells in COPD. Curr. Drug Targets 2011, 12, 460–468. [Google Scholar] [CrossRef] [PubMed]
- Kasahara, Y.; Tuder, R.M.; Cool, C.D.; Lynch, D.A.; Flores, S.C.; Voelkel, N.F. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 2001, 163, 737–744. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Imai, K.; Mercer, B.A.; Schulman, L.L.; Sonett, J.R.; D’Armiento, J.M. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur. Respir. J. 2005, 25, 250–258. [Google Scholar] [CrossRef] [Green Version]
- Makris, D.; Vrekoussis, T.; Izoldi, M.; Alexandra, K.; Katerina, D.; Dimitris, T.; Michalis, A.; Tzortzaki, E.; Siafakas, N.M.; Tzanakis, N. Increased apoptosis of neutrophils in induced sputum of COPD patients. Respir. Med. 2009, 103, 1130–1135. [Google Scholar] [CrossRef] [Green Version]
- Aoshiba, K.; Yokohori, N.; Nagai, A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am. J. Respir. Cell Mol. Biol. 2003, 28, 555–562. [Google Scholar] [CrossRef]
- Fond, A.M.; Ravichandran, K.S. Clearance of Dying Cells by Phagocytes: Mechanisms and Implications for Disease Pathogenesis. Adv. Exp. Med. Biol. 2016, 930, 25–49. [Google Scholar] [CrossRef] [PubMed]
- Yvan-Charvet, L.; Pagler, T.A.; Seimon, T.A.; Thorp, E.; Welch, C.L.; Witztum, J.L.; Tabas, I.; Tall, A.R. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ. Res. 2010, 106, 1861–1869. [Google Scholar] [CrossRef] [Green Version]
- Gonzalez, A.N.; Bensinger, S.J.; Hong, C.; Beceiro, S.; Bradley, M.N.; Zelcer, N.; Deniz, J.; Ramirez, C.; Diaz, M.; Gallardo, G.; et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31, 245–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kotlyarov, S.N.; Kotlyarova, A.A. Participation of ABCA1 transporter in development of chronic obstructive pulmonary disease. Pavlov. Russ. Med Biol. Her. 2020, 28, 360–370. [Google Scholar] [CrossRef]
- Boada-Romero, E.; Martinez, J.; Heckmann, B.L.; Green, D.R. The clearance of dead cells by efferocytosis. Nat. Rev. Mol. Cell Biol. 2020, 21, 398–414. [Google Scholar] [CrossRef] [PubMed]
- Segawa, K.; Nagata, S. An Apoptotic ’Eat Me’ Signal: Phosphatidylserine Exposure. Trends Cell Biol. 2015, 25, 639–650. [Google Scholar] [CrossRef] [PubMed]
- Nishi, C.; Yanagihashi, Y.; Segawa, K.; Nagata, S. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation. J. Biol. Chem. 2019, 294, 7221–7230. [Google Scholar] [CrossRef]
- Lemke, G. Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands. Trends Biochem. Sci. 2017, 42, 738–748. [Google Scholar] [CrossRef]
- Kazeros, A.; Harvey, B.G.; Carolan, B.J.; Vanni, H.; Krause, A.; Crystal, R.G. Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers. Am. J. Respir. Cell Mol. Biol. 2008, 39, 747–757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gonzalez, A.N.; Hidalgo, A. Nuclear Receptors and Clearance of Apoptotic Cells: Stimulating the Macrophage’s Appetite. Front. Immunol. 2014, 5, 211. [Google Scholar] [CrossRef] [Green Version]
- Fond, A.M.; Lee, C.S.; Schulman, I.G.; Kiss, R.S.; Ravichandran, K.S. Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J. Clin. Investig. 2015, 125, 2748–2758. [Google Scholar] [CrossRef]
- Das, S.; Owen, K.A.; Ly, K.T.; Park, D.; Black, S.G.; Wilson, J.M.; Sifri, C.D.; Ravichandran, K.S.; Ernst, P.B.; Casanova, J.E. Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram-negative bacteria. Proc. Natl. Acad. Sci. USA 2011, 108, 2136–2141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moon, S.Y.; Shin, S.A.; Oh, Y.S.; Park, H.H.; Lee, C.S. Understanding the Role of the BAI Subfamily of Adhesion G Protein-Coupled Receptors (GPCRs) in Pathological and Physiological Conditions. Genes 2018, 9, 597. [Google Scholar] [CrossRef] [Green Version]
- Szucs, B.; Szucs, C.; Petrekanits, M.; Varga, J.T. Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article. Int. J. Mol. Sci. 2019, 20, 329. [Google Scholar] [CrossRef] [Green Version]
- Liebow, A.A. Pulmonary emphysema with special reference to vascular changes. Am. Rev. Respir. Dis. 1959, 80, 67–93. [Google Scholar] [CrossRef]
- Green, C.E.; Turner, A.M. The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD). Respir. Res. 2017, 18, 20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hogg, J.C.; Chu, F.; Utokaparch, S.; Woods, R.; Elliott, W.M.; Buzatu, L.; Cherniack, R.M.; Rogers, R.M.; Sciurba, F.C.; Coxson, H.O.; et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350, 2645–2653. [Google Scholar] [CrossRef]
- Kanazawa, H.; Yoshikawa, J. Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest 2005, 128, 3191–3197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Santos, S.; Peinado, V.I.; Ramirez, J.; Morales-Blanhir, J.; Bastos, R.; Roca, J.; Rodriguez-Roisin, R.; Barbera, J.A. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003, 167, 1250–1256. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, M.; Betsuyaku, T.; Nagai, K.; Fuke, S.; Nasuhara, Y.; Kaga, K.; Kondo, S.; Hamamura, I.; Hata, J.; Takahashi, H.; et al. Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients. Inhal. Toxicol. 2008, 20, 349–359. [Google Scholar] [CrossRef]
- Bates, D.O. Vascular endothelial growth factors and vascular permeability. Cardiovasc. Res. 2010, 87, 262–271. [Google Scholar] [CrossRef] [Green Version]
- Tang, K.; Rossiter, H.B.; Wagner, P.D.; Breen, E.C. Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. J. Appl. Physiol. 2004, 97, 1559–1566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGrath-Morrow, S.A.; Cho, C.; Cho, C.; Zhen, L.; Hicklin, D.J.; Tuder, R.M. Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development. Am. J. Respir. Cell Mol. Biol. 2005, 32, 420–427. [Google Scholar] [CrossRef] [Green Version]
- Zhu, L.; Gu, Q.; Fang, L. Cholesterol-mediated regulation of angiogenesis: An emerging paradigm. Cardiol. Plus 2019, 4, 1–9. [Google Scholar] [CrossRef]
- Noghero, A.; Perino, A.; Seano, G.; Saglio, E.; Lo Sasso, G.; Veglio, F.; Primo, L.; Hirsch, E.; Bussolino, F.; Morello, F. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. Arter. Thromb. Vasc. Biol. 2012, 32, 2280–2288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Labrecque, L.; Royal, I.; Surprenant, D.S.; Patterson, C.; Gingras, D.; Beliveau, R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell 2003, 14, 334–347. [Google Scholar] [CrossRef]
- Liao, W.X.; Feng, L.; Zhang, H.; Zheng, J.; Moore, T.R.; Chen, D.B. Compartmentalizing VEGF-induced ERK2/1 signaling in placental artery endothelial cell caveolae: A paradoxical role of caveolin-1 in placental angiogenesis in vitro. Mol. Endocrinol. 2009, 23, 1428–1444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zou, J.; Lei, T.; Guo, P.; Yu, J.; Xu, Q.; Luo, Y.; Ke, R.; Huang, D. Mechanisms shaping the role of ERK1/2 in cellular senescence (Review). Mol. Med. Rep. 2019, 19, 759–770. [Google Scholar] [CrossRef] [Green Version]
- Lu, Z.; Xu, S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006, 58, 621–631. [Google Scholar] [CrossRef]
- Zhou, X.; Yin, Z.; Guo, X.; Hajjar, D.P.; Han, J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J. Biol. Chem. 2010, 285, 6316–6326. [Google Scholar] [CrossRef] [Green Version]
- Mulay, V.; Wood, P.; Manetsch, M.; Darabi, M.; Cairns, R.; Hoque, M.; Chan, K.C.; Reverter, M.; Alvarez-Guaita, A.; Rye, K.A.; et al. Inhibition of mitogen-activated protein kinase Erk1/2 promotes protein degradation of ATP binding cassette transporters A1 and G1 in CHO and HuH7 cells. PLoS ONE 2013, 8, e62667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xue, X.H.; Shi, F.F.; Chen, T.; Wei, W.; Zhou, X.M.; Chen, L.D. Inhibition of ERK1/2 improves lipid balance in rat macrophages via ABCA1/G1 and CD36. Mol. Med. Rep. 2016, 13, 1533–1540. [Google Scholar] [CrossRef] [Green Version]
- Cannizzo, C.M.; Adonopulos, A.A.; Solly, E.L.; Ridiandries, A.; Vanags, L.Z.; Mulangala, J.; Yuen, S.C.G.; Tsatralis, T.; Henriquez, R.; Robertson, S.; et al. VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemia. FASEB J. 2018, 32, 2911–2922. [Google Scholar] [CrossRef] [Green Version]
- Christoffersen, C.; Nielsen, L.B. Apolipoprotein M: Bridging HDL and endothelial function. Curr. Opin Lipidol. 2013, 24, 295–300. [Google Scholar] [CrossRef]
- Christoffersen, C.; Obinata, H.; Kumaraswamy, S.B.; Galvani, S.; Ahnstrom, J.; Sevvana, M.; Egerer-Sieber, C.; Muller, Y.A.; Hla, T.; Nielsen, L.B.; et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. USA 2011, 108, 9613–9618. [Google Scholar] [CrossRef] [Green Version]
- Ruiz, M.; Frej, C.; Holmer, A.; Guo, L.J.; Tran, S.; Dahlback, B. High-Density Lipoprotein-Associated Apolipoprotein M Limits Endothelial Inflammation by Delivering Sphingosine-1-Phosphate to the Sphingosine-1-Phosphate Receptor 1. Arter. Thromb. Vasc. Biol. 2017, 37, 118–129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vaidya, M.; Jentsch, J.A.; Peters, S.; Keul, P.; Weske, S.; Graler, M.H.; Mladenov, E.; Iliakis, G.; Heusch, G.; Levkau, B. Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages. J. Lipid Res. 2019, 60, 506–515. [Google Scholar] [CrossRef] [Green Version]
- Jin, F.; Hagemann, N.; Sun, L.; Wu, J.; Doeppner, T.R.; Dai, Y.; Hermann, D.M. High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation. Angiogenesis 2018, 21, 381–394. [Google Scholar] [CrossRef] [PubMed]
- Tan, J.T.; Ng, M.K.; Bursill, C.A. The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovasc. Res. 2015, 106, 184–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prosser, H.C.; Tan, J.T.; Dunn, L.L.; Patel, S.; Vanags, L.Z.; Bao, S.; Ng, M.K.; Bursill, C.A. Multifunctional regulation of angiogenesis by high-density lipoproteins. Cardiovasc. Res. 2014, 101, 145–154. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Tang, C. Regulation of ABCA1 functions by signaling pathways. Biochim. Biophys. Acta 2012, 1821, 522–529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kotlyarov, S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci. 2021, 22, 3334. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073334
Kotlyarov S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences. 2021; 22(7):3334. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073334
Chicago/Turabian StyleKotlyarov, Stanislav. 2021. "Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease" International Journal of Molecular Sciences 22, no. 7: 3334. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073334